Field 1 – Disease Models
These models range from state-of-the-art in vitro models like 3D cultures, organoids and organs-on-a-chip towards in vivo, patient-proximate models and advanced precision cancer models generated using CRISPR-Cas9. They are used to study a wide range of cancer topics like tumour progression, metastasis and tumour resistance aiming to find novel treatment options. Cancer disease models are therefore at the core in understanding cancer biology, identifying markers of cancer and prognosis, and for the development and testing of general and personalised therapeutics.
| Unique ID | Country | Service Name | Description of Service | Research Infrastructure | Service Provider | Unit of access | Website |
|---|---|---|---|---|---|---|---|
| 1.3_BIOGEM scarl | IT | Generation of zebrafish model of cancer by genetic manipulation | The service generates different zebrafish models of cancers. For the generation of genetically modified model of cancer, the service include the strategy design, preparation of the documentation for the authorization, the vectors preparation to realize them by TOL2 mediated transgenesis or CrispR/Cas9 technology. For the xenograft models of cancer the service include all the steps behind in the injection in zebrafish embryos that can be conducted in yolk sac and Couvier duct. | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | BIOGEM scarl | Zebrafish model generation | https://www.biogem.it/index.php/en/ |
| 1.12_BRFAA | GR | Generation of healthy and cancer tissue organoids | In this service, the stem cells obtained from the tissues will be used for the generation of organoid cultures as 3D models for the study of cancer diseases as well as the evaluation of the first-line drugs and innovative drugs' effects. Support will be provided in the characterization of drugs approved by European and international drug agencies or in development. New formulations and/or combinations of drugs adapted to the molecular and genetic characteristics of the disease will be identified. The effect, toxicity, and therapeutic response will be evaluated with respect to classic chemotherapeutic agents | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | Biomedical Research Foundation (BRFAA) of the Academy of Athens | Healthy and tumour organoids | http://www.bioacademy.gr |
| 1.14_IFO-IRCCS National | IT | Generation of ascitic-derived ovarian cancer organoids | This service provides the generation of organoids from ovarian cancer ascites. If the organoids are generated from internal bio specimens they will also be accompanied with histopathologically and clinically characterization according with our Pathology Unit standards. | IFO-IRE | Istituti Fisioterapici Ospitalieri - IRCCS Istituto Nazionale Tumori Regina Elena (IFO-IRE) | Ascitic-derived ovarian cancer organoids | https://www.ifo.it |
| 1.13_IFO-IRCCS National | IT | Generation of organoid cultures from primary and metastatic breast cancer tissues | This service provides the generation of organoids from both primary breast cancers and/or matched/unmatched breast metastases in different organs. If the organoids are generated from internal bio specimens they will also be accompanied with histopathologically and clinically characterization according with our Pathology Unit standards. | IFO-IRE | Istituti Fisioterapici Ospitalieri - IRCCS Istituto Nazionale Tumori Regina Elena (IFO-IRE) | Organoid cult. from prim. & metast. b. c. tissues | https://www.ifo.it |
| 1.15_IFO-IRCCS | IT | Availability of organoid cultures from primary and metastatic breast cancer tissues | This service provides the availability of organoids, or properly preserved tissues to generate organoids, from both primary breast cancers and/or matched/unmatched breast metastases in different organs. They will also be accompanied with histopathologically and clinically characterization according with our Pathology Unit standards. | IFO-IRE | Istituti Fisioterapici Ospitalieri - IRCCS Istituto Nazionale Tumori Regina Elena (IFO-IRE) | Organoid cult. from prim. & metast. breast cancer | https://www.ifo.it |
| 1.16_BMF | AT | Co-culture and 3D models (autologous models) | Co-culture and 3D models (autologous models): In tumors, there is a great diversity in the expression of protein biomarkers and different genetic and epigenetic variants. Heterogeneity of tumors in a widely branched tumor architecture is often the reason for proliferation, aggressiveness, tumorigenicity, angiogenesis and chemoresistance. A major possibility to increase the informative value of in vitro experiments with respect to their in vivo relevance is the establishment and use of primary (near organ) cell and tissue cultures. Especially in combination with special cell culture techniques, such as cocultivation, cultivation under hypoxic conditions, etc., processes and conditions essential for cancer research can be simulated, reproduced and investigated in a standardized way. Thus, a connection to clinical relevance and personalized medicine can be established. Co-Culture in vitro models are a reproducible, well characterized, easy-to-handle and time-efficient model that mimics the physiology of tumors and can be used for addressing tumor desmoplasia, signal-transduction studies, tumor progression and cell-to-cell communication as well as for therapy- and resistance studies in vitro and in vivo. | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | MedUniGraz | Co-culture and 3D models | https://biomedizinische-forschung.medunigraz.at/en/ |
| 1.17_BIOGEM-Scarl | IT | Organoid generation | Generation of human and murine endodermal organoids from biopsies of different type of cancers from living cells. Frozen samples can be also used and protocol for the preparation of the sample will be furnished. At least 4 organoids will be generated for each sample | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | BIOGEM scarl | Human and murine organoids from cancer biopsies | https://www.biogem.it/index.php/en/ |
| 1.18_BIOGEM-Scarl | IT | Organoid genome editing | The organoids genome editing service includes both TALEN and CRISPR/Cas9 technology. In particular, it provides the generation of TALEN constructs as well as organoid transfection to perform either knockout or knock-in genome editing. The service also includes the prediction of off-target sites, the preparation of sgRNAs and Cas9 RNA/protein, and organoid cultures transduction. | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | BIOGEM scarl | Organoid genome editing | https://www.biogem.it/index.php/en/ |
| 1.4_BIOGEM Scarl | IT | Zebrafish model phenotyping for biomarker validation | The service includes the evaluation of phenotyc parameters of general health (growth, reproduction, etc.) or analysing of pathological features by microscopic (histo-chemistry or immuno-histochemistry) and molecular approaches (RTqPCR, etc.). Phenotyping and biomarker validation can be performed by in vivo imaging approaches ( including confocal microscopy and 2-photon microscopy on request) in embryos and transparent adults allowing the monitoring at single cell level of the cancer cell. | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | BIOGEM scarl | Biomarker validation | https://www.biogem.it/index.php/en/ |
| 1.5_BIOGEM Scarl | IT | Xenograft in zebrafish embryos for biomarker validation | The service includes the support in project design and set up from the choosing of the fluorescent vital dye to the injection site (yolk sac or Couvier duct or both). PDX can be developed. The service includes: cell expantion and staining, cell injection in zebrafish embryos imaging , within 3 days post-injection, and data analyses. Imaging can be conducted with different approaches including confocal microscopy and 2-photon microscopy on request. | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | BIOGEM scarl | Zebrafish xenograft | https://www.biogem.it/index.php/en/ |
| 1.6_BRFAA | GR | CRISPR/Cas-mediated gene knockout in primary cultures | In this service, BRFAA will design a set of guide guide RNAs against an indicated target, clone these RNAs in appropriate vectors and introduce them into primary cultures of choice together with Cas9-encoding vectors. Fluorescent protein reporters will be used to FACS transfected cells. The targeting efficiency will be assessed via PCR. | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | Biomedical Research Foundation (BRFAA) of the Academy of Athens | CRISP-Cas9 mediated knock out in primary cultures | http://www.bioacademy.gr |
| 1.7_BRFAA | GR | Generation of organoids from bladder, lung, gastrointestinal, head and neck cancer, breast, pancreatic cancers, glioblastoma and other neural tumors | Tissue biopsies from human or mouse tumor samples will be processed for the generation of single suspensions for culturing on ECM-like hydrogels. Cultures will be established and passaged at least once. These cultures could be harvested for molecular analysis, fixed for histological evaluation etc. | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | Biomedical Research Foundation (BRFAA) of the Academy of Athens | Organoid generation form various kinds of tumours | http://www.bioacademy.gr |
| 1.8_BMF | AT | Cancer associated fibroblasts | Cancer associated fibroblasts from the same patient to mimik the in vivo situation: Most of the surrounding tissue consists of cancer-associated fibroblasts (CAFs). CAFs will be immortalized using hTERT technologies to extend CAF lifespan. Both cell lines (tumor and CAFs) will be characterized in detail phenotypically and gendotypically. Both patient-derived cell lines will be used to produce 3D spheroids and/or co-culture. Tumor cells and immortalized fibroblasts from the same patient represent an ideal in vitro model to explore the biology of tumors and novel therapies could be tested, These models demonstrate the importance of tailored therapies in tumor research. | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | MedUniGraz | Cancer associated fibroblasts | https://biomedizinische-forschung.medunigraz.at/en/ |
| 1.9_BMF | AT | Patient derived cell lines | Cancer patient derived cell lines (long term culture): Immediately after surgery, the tissue is further processed in the cell culture lab after thorough diagnostics at the Institute of Pathology in order to establish patient-derived cell lines. The tumor and surrounding tissue are separated using various removal and seeding methods and both tissues are processed mechanically and enzymatically.The tumor cells are further passaged, and after overcoming the Hayflick limit, they become continuously growing cell lines. In many tumor types, but especially in tumors of the pancreas or bile ducts, the tumor microenvironment plays a crucial role. Therefore, in order to approximate tumor models as closely as possible to the in vivo state, the surrounding tissue must also be preserved for research. Cell lines will be characterized in detail phenotypically and gendotypically. | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | MedUniGraz | Patient derived cell lines | https://biomedizinische-forschung.medunigraz.at/en/ |
| 1.10_CBMED | AT | Generation of patient-derived tumor cells (PDCs) | This service includes the isolation of primary tumor cells from human tumor tissue and the generation of shor term spheroid cultures. These spheroids can be used for downstream analysis, such as genomic analysis, immuno-histochemistry or drug response experiments. A comprehensive panel of genomic information and histological information about the source tumor can be delivered together with the spheroids. | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | Center for Biomarker Research in Medicine GmbH | 1 PDC generation | https://www.cbmed.at/ |
| 1.11_BRFAA | GR | Generation of organ-on-chip platform | Tissue biopsies from healthy or cancer tissue will be cultured onto organ-on-chip platforms (as simple as transwell or more complex compartmentalized microfluidic devices). Tissue can be cultured as single cell suspension, explants or even tissue slices if biopsy size allows. | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | Biomedical Research Foundation (BRFAA) of the Academy of Athens | Organ-on-a-chip platform | http://www.bioacademy.gr |
| 1.20a_NKI | NL | Generation of precision cancer mouse models using CRISPR-Cas9 | The precision cancer mouse model generation service uses CRISPR-Cas9 technology to design precise and unique cancer mouse models. This service includes prediction of off-target sites, preparation of sgRNA’s and Cas9 mRNA/protein, and injection into zygotes to generate F0 founder mutant animals (C57BL/6N or C57BL/6J genetic background preferred). Selected F0 animals will be bred to germline to produce F1 genome edited animals. Possible allele types that can be generated are indels, exon deletions (< 10kb) and point mutation insertions. Newly developed mouse models will be made available to selected applicants within an average of 12 months following provision of all required information to start the mouse production. | INFRAFRONTIER ERIC | The Netherlands Cancer Institute | Mouse model generation | https://www.nki.nl |
| 1.26b_UMG AV CR | CZ | In-depth cancer-based phenotyping of cancer mouse models | This specialised mouse phenotyping service is directed towards cancer mouse models and combines mouse breeding and experimental animal pathology. The mouse breeding includes the breeding, genotyping and selection of the mice that will be phenotyped. The mouse handling involves the bi-weekly palpation of the mice, measuring the tumors and checking for metastasis and overall welfare. It also involves sacrificing the mice for dissection and freezing down and storing the viable tumor pieces. A health check will be performed and tumors genotyped. The experimental animal pathology encompasses the complete necropsy of 15 mice, followed by complete histology (tissue trimming, processing, paraffin embedding, sectioning, staining with hematoxylin and eosin), and histopathology report of all abnormalities (phenotypes) of several body parts and organs. | INFRAFRONTIER ERIC | Institute of Molecular Genetics of the ASCR, v.v.i. | Cancer phenotyping of mouse models | https://www.phenogenomics.cz |
| 1.27_FCG-IGC | PT | Cancer and microbiota interaction pipeline | The access unit covers the derivation of a single mouse mutant line into a germ-free condition, from a breeding nucleus or from frozen materials provided by the applicants. Mice will be kept under germ-free conditions for 12 weeks. The service includes the access to tumor samples, organs, tissues and biofluids from the germ-free mice (and SPF controls if requested). Tumor follow-up and solid tumor size will be measured following guidelines provided by the applicants. Mutant mouse lines will be provided by the selected applicants as live animals (minimum of 10 females and 5 males) or quality controlled frozen embryos or sperm (minimum of 40 embryos or 2 straws of sperm). The service provider will transfer and breed mice under SPF conditions (if SPF controls are needed), and introduce and foster 2 litters or 8 animals into one germ-free isolator until 3 months of age. | INFRAFRONTIER ERIC | Instituto Gulbenkian de Ciência | Axenic rederivation of can. models & tumor studies | https://gulbenkian.pt/ciencia/ |
| 1.20b_HMGU | DE | Generation of precision cancer mouse models using CRISPR-Cas9 | The precision cancer mouse model generation service uses CRISPR-Cas9 technology to design precise and unique cancer mouse models. This service includes prediction of off-target sites, preparation of sgRNA’s and Cas9 mRNA/protein, and injection into zygotes to generate F0 founder mutant animals (C57BL/6N or C57BL/6J genetic background preferred). Selected F0 animals will be bred to germline to produce F1 genome edited animals. Possible allele types that can be generated are indels, exon deletions (< 10kb) and point mutation insertions. Newly developed mouse models will be made available to selected applicants within an average of 12 months following provision of all required information to start the mouse production. | INFRAFRONTIER ERIC | Helmholtz Center Munich | Mouse model generation | https://www.helmholtz-munich.de/en/ |
| 1.20g_CERBM-GIE | FR | Generation of precision cancer mouse models using CRISPR-Cas9 | The precision cancer mouse model generation service uses CRISPR-Cas9 technology to design precise and unique cancer mouse models. This service includes prediction of off-target sites, preparation of sgRNA’s and Cas9 mRNA/protein, and injection into zygotes to generate F0 founder mutant animals (C57BL/6N or C57BL/6J genetic background preferred). Selected F0 animals will be bred to germline to produce F1 genome edited animals. Possible allele types that can be generated are indels, exon deletions (< 10kb) and point mutation insertions. Newly developed mouse models will be made available to selected applicants within an average of 12 months following provision of all required information to start the mouse production. | INFRAFRONTIER ERIC | Centre Européen de Recherche en Biologie et Médecine - Groupement d’Intérêt Economique | Mouse model generation | http://www.ics-mci.fr/en/ |
| 1.25a_UKRI | GB | Systematic phenotyping of cancer mouse models | In this service, user-provided mice cohorts are analysed systematically covering a broad range of tests to identify novel phenotypes. These tests and screens analyse the behaviour, neurology, clinical chemistry, nociception, dysmorphology, allergy, energy metabolism, cardiovascular function, sight, immunology and pathology. Missing info: size of the cohort, cost coverage, data provision etc. | INFRAFRONTIER ERIC | MRC Harwell | phenotyp. mouse model | https://www.har.mrc.ac.uk |
| 1.20c_University of Oulu | FI | Generation of precision cancer mouse models using CRISPR-Cas9 | The precision cancer mouse model generation service uses CRISPR-Cas9 technology to design precise and unique cancer mouse models. This service includes prediction of off-target sites, preparation of sgRNA’s and Cas9 mRNA/protein, and injection into zygotes to generate F0 founder mutant animals (C57BL/6N or C57BL/6J genetic background preferred). Selected F0 animals will be bred to germline to produce F1 genome edited animals. Possible allele types that can be generated are indels, exon deletions (< 10kb) and point mutation insertions. Newly developed mouse models will be made available to selected applicants within an average of 12 months following provision of all required information to start the mouse production. | INFRAFRONTIER ERIC | University of Oulu | Mouse model generation | https://www.oulu.fi/en/university/faculties-and-units/biocenter-oulu |
| 1.20d_UMG AV CR | CZ | Generation of precision cancer mouse models using CRISPR-Cas9 | The precision cancer mouse model generation service uses CRISPR-Cas9 technology to design precise and unique cancer mouse models. This service includes prediction of off-target sites, preparation of sgRNA’s and Cas9 mRNA/protein, and injection into zygotes to generate F0 founder mutant animals (C57BL/6N or C57BL/6J genetic background preferred). Selected F0 animals will be bred to germline to produce F1 genome edited animals. Possible allele types that can be generated are indels, exon deletions (< 10kb) and point mutation insertions. Newly developed mouse models will be made available to selected applicants within an average of 12 months following provision of all required information to start the mouse production. | INFRAFRONTIER ERIC | Institute of Molecular Genetics of the ASCR, v.v.i. | Mouse model generation | https://www.phenogenomics.cz |
| 1.20e_UKRI | GB | Generation of precision cancer mouse models using CRISPR-Cas9 | The precision cancer mouse model generation service uses CRISPR-Cas9 technology to design precise and unique cancer mouse models. This service includes prediction of off-target sites, preparation of sgRNA’s and Cas9 mRNA/protein, and injection into zygotes to generate F0 founder mutant animals (C57BL/6N or C57BL/6J genetic background preferred). Selected F0 animals will be bred to germline to produce F1 genome edited animals. Possible allele types that can be generated are indels, exon deletions (< 10kb) and point mutation insertions. Newly developed mouse models will be made available to selected applicants within an average of 12 months following provision of all required information to start the mouse production. | INFRAFRONTIER ERIC | United Kingdom Research and Innovation | Mouse model generation | https://www.har.mrc.ac.uk |
| 1.20f_VetMedUni Vienna | AT | Generation of precision cancer mouse models using CRISPR-Cas9 | The precision cancer mouse model generation service uses CRISPR-Cas9 technology to design precise and unique cancer mouse models. This service includes prediction of off-target sites, preparation of sgRNA’s and Cas9 mRNA/protein, and injection into zygotes to generate F0 founder mutant animals (C57BL/6N or C57BL/6J genetic background preferred). Selected F0 animals will be bred to germline to produce F1 genome edited animals. Possible allele types that can be generated are indels, exon deletions (< 10kb) and point mutation insertions. Newly developed mouse models will be made available to selected applicants within an average of 12 months following provision of all required information to start the mouse production. | INFRAFRONTIER ERIC | University of Veterinary Medicine Vienna | Mouse model generation | https://www.vetmeduni.ac.at/en/in-vivo-and-in-vitro-models |
| 1.25b_HMGU | DE | Systematic phenotyping of cancer mouse models | In this service, user-provided mice cohorts are analysed systematically covering a broad range of tests to identify novel phenotypes. These tests and screens analyse the behaviour, neurology, clinical chemistry, nociception, dysmorphology, allergy, energy metabolism, cardiovascular function, sight, immunology and pathology. Missing info: size of the cohort, cost coverage, data provision etc. | INFRAFRONTIER ERIC | Helmholtz Center Munich | phenotyping mouse models | https://www.helmholtz-munich.de/en/ |
| 1.26a_NKI | NL | In-depth cancer-based phenotyping of cancer mouse models | This specialised mouse phenotyping service is directed towards cancer mouse models and combines mouse breeding and experimental animal pathology. The mouse breeding includes the breeding, genotyping and selection of the mice that will be phenotyped. The mouse handling involves the bi-weekly palpation of the mice, measuring the tumors and checking for metastasis and overall welfare. It also involves sacrificing the mice for dissection and freezing down and storing the viable tumor pieces. A health check will be performed and tumors genotyped. The experimental animal pathology encompasses the complete necropsy of 15 mice, followed by complete histology (tissue trimming, processing, paraffin embedding, sectioning, staining with hematoxylin and eosin), and histopathology report of all abnormalities (phenotypes) of several body parts and organs. | INFRAFRONTIER ERIC | The Netherlands Cancer Institute | Cancer phenotyping of mouse models | https://www.nki.nl |
| 1.1_SU-IMEV | FR | Phallusia transient transgenesis | Access to marine model organisms (ascidians, Phallusia mammillata) and optimized CRISPR-Cas9 genetic manipulation for transgenesis. Breeding and maintenance of animals, genetic manipulation, 3D and live imaging (photonic and quantitative) and complimentary experimental techniques. RNA/DNA/protein injection of Phallusia mammillata oocytes followed by fertilization to obtain transgenic phallusia embryos expressing the protein product of interest | EUROPEAN MARINE BIOLOGICAL RESOURCE CENTRE EUROPEAN RESEARCH INFRASTRUCTURE CONSORTIUM (EMBRC-ERIC) | Institut de la mer de Villefranche | Marine models | http://www.obs-vlfr.fr/web/index.php |
| 1.2_SZN | IT | Ascidian model organisms | Access to marine model organisms (ascidians, Ciona robusta) and optimized CRISPR-Cas9 genetic manipulation for transgenesis. Breeding and maintenance of animals, genetic manipulation, 3D and live imaging and complimentary experimental techniques | EUROPEAN MARINE BIOLOGICAL RESOURCE CENTRE EUROPEAN RESEARCH INFRASTRUCTURE CONSORTIUM (EMBRC-ERIC) | Stazione Zoologica Anton Dohrn | Marine models | http://www.szn.it |
| 1.29d_EurOPDX | ES | Biobanking at the EurOPDX infrastructure of a user-supplied patient-derived xenograft (PDX) model. | The user’s PDX model will be health checked according to our Health monitoring SOP and, if cleared, expanded, biobanked, and quality controlled (histology, identity check , health monitoring). Model metadata and, if available, molecular data will be collected and included in the public EurOPDX Data Portal (https://dataportal.europdx.eu/). The infrastructure will generate for the model a PDX passport, a factsheet containing all main features of the model, such as histology, strain, growth characteristics, health check, and ethical check. Users’ models will be made available to the scientific community through the SAMPLE service described above, or on a collaborative basis depending on the situation. | EurOPDX (UNIVERSITA DEGLI STUDI DI TORINO) | Vall d'Hebron Institute of Oncology | 1 PDX model | https://dataportal.europdx.eu/ |
| 1.28d_EurOPDX | ES | Shipment of a frozen patient-derived xenograft (PDX) sample to academic laboratories. | One PDX model selected by the user on the EurOPDX Data Portal (https://dataportal.europdx.eu/) is rescued from the biobank, engrafted and expanded in NGS mice, then explanted for generating vital frozen aliquots. One aliquot is shipped to the user together with a PDX passport, a factsheet developed by the EurOPDX RI to contain all the main features of a given PDX model, such as histology, strain, growth characteristics. All models are Quality Controlled: histology, health check, and genetic fingerprinting. | EurOPDX (UNIVERSITA DEGLI STUDI DI TORINO) | Vall d'Hebron Institute of Oncology | 1 PDX model | https://dataportal.europdx.eu/ |
| 1.30_IIS Aragon | ES | Generation of vascularised Tumoroid and Organoids from endodermal derived tissues | Vascularized Tumoroid and Organoid Generation with native blood vessels and large-scale expansion from endodermal derived tissues organoids | EATRIS ERIC (EATRIS) | IIS Aragón: IISA – Instituto de Investigación Sanitaria Aragón | Disease model / tissue model | https://www.iisaragon.es/ |
| 1.31_IIS Aragon | ES | Generation of cell-based 3D diseases models | Biopsy derived cells to generate advanced 3D disease models (organoids or tumoroids) added with immune, stromal and endothelial cells. | EATRIS ERIC (EATRIS) | IIS Aragón: IISA – Instituto de Investigación Sanitaria Aragón | Disease model / tissue model | https://www.iisaragon.es/ |
| 1.34_ISS | IT | Microfluidic Devices generation | Microfluidic Devices for Immune surveillance and drug testing | EATRIS ERIC (EATRIS) | Istituto Superiore di Sanità (ISS) | 1 run experiment (2 devices) | https://www.iss.it/ |
| 1.36_(iMM) | PT | Reprogramming of patient cells into iPSc | Reprogramming patient cells from blood samples or skin biopsies to iPSCs. Focus on patients harbouring mutations in cancer susceptibility genes. | EATRIS ERIC (EATRIS) | Instituto de Medicina Molecular João Lobo Antunes (iMM) | Patient-derived iPSC cells | https://imm.medicina.ulisboa.pt/ |
| 1.32_ISS | IT | Generation of oganoids | Generation, expansion and validation of organoids from normal and neoplastic tissues | EATRIS ERIC (EATRIS) | Istituto Superiore di Sanità (ISS) | 1set of organo. (max.2) deriv. from5/6 surg. samp. | https://www.iss.it/ |
| 1.33_ISS | IT | Tumor-on-chip analysis | High throughput analysis of Tumor-on-Chip for dissecting the crosstalk between immune cells and cancer to obtain detailed morphodynamic and kinematic datasets. Automated high throughput analysis of cells (morphodynamic and kinematic parameters) and cell-cell interaction processing algorithms. Generation of ad hoc Matlab/R/ImageJ scripts for image optimization and scaling. | EATRIS ERIC (EATRIS) | Istituto Superiore di Sanità (ISS) | sample pair | https://www.iss.it/ |
| 1.37_VHIR | ES | Generation of cancer stem cell (CSC) model | Cancer stem cell (CSC) model generation to: i) understand the CSC dynamics, ii) track the efficacy of anti-CSC drugs and iii) evaluate the efficacy of CSC-targeted delivery systems (3–7). This model can be used to study the role of extracellular vesicles (EV) of CSC and non-CSC in the tumour growth and dissemination. | EATRIS ERIC (EATRIS) | Vall d'Hebron Research Institute (VHIR) | Cancer stem cell model | https://vhir.vallhebron.com/ |
| 1.38_IRST | IT | 3D collagen biomimetic scaffolds generation | Study of tumour characteristics on -3D collagen biomimetic scaffolds on cancer cell lines and primary cells of solid tumours and in particular rare tumours as NEN, Sarcomas, H&N tumours, low grade gliomas and bone metastases from solid tumours. -De-cellularized dermal scaffolds and 3-D scaffold free models multicellular (homotypic and heterotypic) | EATRIS ERIC (EATRIS) | Istituto Tumori della Romagna IRST IRCCS | Disease model of 1 cancer cell line | https://www.irst.emr.it/it/ |
| 1.39_PFP LIH | LU | Organoid culture: Personalized Functional Profiling (PFP) | Analysis of the viability of ex-vivo tumor spheroids or organoids developed from the patient’s tumor sample in response to a selected drug panel. The functional drug response of the patient’s tumor spheroids/organoids is expected to provide treatment recommendations within 4-6 weeks (from the time of sample collection). This procedure is mainly applied for advanced-stage cancers | EATRIS ERIC (EATRIS) | Luxembourg Institute of Health (LIH) | Tumor specimen | https://www.lih.lu/en/ |
| 1.28a_D.Oncology | IT | Shipment of a frozen patient-derived xenograft (PDX) sample to academic laboratories. | One PDX model selected by the user on the EurOPDX Data Portal (https://dataportal.europdx.eu/) is rescued from the biobank, engrafted and expanded in NGS mice, then explanted for generating vital frozen aliquots. One aliquot is shipped to the user together with a PDX passport, a factsheet developed by the EurOPDX RI to contain all the main features of a given PDX model, such as histology, strain, growth characteristics. All models are Quality Controlled: histology, health check, and genetic fingerprinting. | EurOPDX (UNIVERSITA DEGLI STUDI DI TORINO) | University of Torino | 1 PDX model | https://dataportal.europdx.eu/ |
| 1.28b_IC | FR | Shipment of a frozen patient-derived xenograft (PDX) sample to academic laboratories. | One PDX model selected by the user on the EurOPDX Data Portal (https://dataportal.europdx.eu/) is rescued from the biobank, engrafted and expanded in NGS mice, then explanted for generating vital frozen aliquots. One aliquot is shipped to the user together with a PDX passport, a factsheet developed by the EurOPDX RI to contain all the main features of a given PDX model, such as histology, strain, growth characteristics. All models are Quality Controlled: histology, health check, and genetic fingerprinting. | EurOPDX (UNIVERSITA DEGLI STUDI DI TORINO) | Institut Curie | 1 PDX model | https://dataportal.europdx.eu/ |
| 1.28c_NKI | NL | Shipment of a frozen patient-derived xenograft (PDX) sample to academic laboratories. | One PDX model selected by the user on the EurOPDX Data Portal (https://dataportal.europdx.eu/) is rescued from the biobank, engrafted and expanded in NGS mice, then explanted for generating vital frozen aliquots. One aliquot is shipped to the user together with a PDX passport, a factsheet developed by the EurOPDX RI to contain all the main features of a given PDX model, such as histology, strain, growth characteristics. All models are Quality Controlled: histology, health check, and genetic fingerprinting. | EurOPDX (UNIVERSITA DEGLI STUDI DI TORINO) | Netherlands Cancer Institute | 1 PDX model | https://dataportal.europdx.eu/ |
| 1.29a_D.Oncology | IT | Biobanking at the EurOPDX infrastructure of a user-supplied patient-derived xenograft (PDX) model. | The user’s PDX model will be health checked according to our Health monitoring SOP and, if cleared, expanded, biobanked, and quality controlled (histology, identity check , health monitoring). Model metadata and, if available, molecular data will be collected and included in the public EurOPDX Data Portal (https://dataportal.europdx.eu/). The infrastructure will generate for the model a PDX passport, a factsheet containing all main features of the model, such as histology, strain, growth characteristics, health check, and ethical check. Users’ models will be made available to the scientific community through the SAMPLE service described above, or on a collaborative basis depending on the situation. | EurOPDX (UNIVERSITA DEGLI STUDI DI TORINO) | University of Torino | 1 PDX model | https://dataportal.europdx.eu/ |
| 1.29b_IC | FR | Biobanking at the EurOPDX infrastructure of a user-supplied patient-derived xenograft (PDX) model. | The user’s PDX model will be health checked according to our Health monitoring SOP and, if cleared, expanded, biobanked, and quality controlled (histology, identity check , health monitoring). Model metadata and, if available, molecular data will be collected and included in the public EurOPDX Data Portal (https://dataportal.europdx.eu/). The infrastructure will generate for the model a PDX passport, a factsheet containing all main features of the model, such as histology, strain, growth characteristics, health check, and ethical check. Users’ models will be made available to the scientific community through the SAMPLE service described above, or on a collaborative basis depending on the situation. | EurOPDX (UNIVERSITA DEGLI STUDI DI TORINO) | Institut Curie | 1 PDX model | https://dataportal.europdx.eu/ |
| 1.29c_NKI | NL | Biobanking at the EurOPDX infrastructure of a user-supplied patient-derived xenograft (PDX) model. | The user’s PDX model will be health checked according to our Health monitoring SOP and, if cleared, expanded, biobanked, and quality controlled (histology, identity check , health monitoring). Model metadata and, if available, molecular data will be collected and included in the public EurOPDX Data Portal (https://dataportal.europdx.eu/). The infrastructure will generate for the model a PDX passport, a factsheet containing all main features of the model, such as histology, strain, growth characteristics, health check, and ethical check. Users’ models will be made available to the scientific community through the SAMPLE service described above, or on a collaborative basis depending on the situation. | EurOPDX (UNIVERSITA DEGLI STUDI DI TORINO) | Netherlands Cancer Institute | 1 PDX model | https://dataportal.europdx.eu/ |
| 1.22_USC | ES | Development and validation of in-vitro models for cancer invasiveness in complex models | Development and validation of scaffold-based 3D models to investigate cancer invasiveness on surrounding tissue using our state-of-the-art drug development platform (INNOpharma). First, a collagen I matrix is prepared by polymerization at 37 °C. Endothelial cells are seeded on top of the collagen layer and incubated for 24h, followed by a seeding of fluorescently labeled tumor cells on top of these endothelial cells. Cells are incubated with compounds for 7 days. Each well will be analyzed by automated fluorescence microscopy in confocal mode with an Operetta CLS automatic imaging system (PerkinElmer, with 5 µm planes) to quantify the number of tumoral cells within the endothelial layer. | EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC) | University of Santiago de Compostela | complex invasiveness model | |
| 1.23_USC | ES | Development and validation of co-culture, in-vitro models of cancer and immune cells | Development and validation of co-cultures of cancer and immune cells to investigate the immune response on cancer cells using our state-of-the-art drug development platform (INNOpharma). The assays consist of seeding the fluorescently-stained tumoral cells in an agarose matrix for achieving a tumor spheroid. After 6 days of cell culture PBMCs previously stained with CellTracker Orange are seeded. On day 8 compounds are added to the wells. After 10 days of co-culture, microscopy images are obtained by automated fluorescence microscopy in confocal mode with an Operetta CLS automatic imaging system (PerkinElmer) with planes each 1 µm and the spheroid size, volume, and tumor-infiltrating lymphocytes are quantified. | EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC) | University of Santiago de Compostela | co-culture model | |
| 1.24a_SINTEF | NO | Generation and validation of in-vitro disease model (2/3D cultures and organoids) | Generation and validation of in-vitro disease model (2/3D cultures and organoids) | EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC) | SINTEF | 3D culture model | https://www.sintef.no/en/ |
| 1.24b_ITMP | DE | Generation and validation of in-vitro disease model (2/3D cultures and organoids) | The generation of 3D organoids for standard disease model that will be suitable for standard cell viability and multi-parametric high-content microscopy readouts. | EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC) | Fraunhofer Institute for Translational Medicine and Pharmacology | in-vitro disease model | |
| 1.24c_CIPF | ES | Generation of 3D organoids from patient-derived breast cancer tissue | The generation of 3D organoids from either primary breast cancer tumors (approximately 1 cm3) or skin metastasis derived from primary breast cancer, following the method published by Sachs et al (Cell, 2018) (ethical requisites in place including inform consent). We obtain heterogeneous cultures, with differences in number of organoids, compactness, and roundness. Moreover, growth rates differ between organoid cultures, with time needed to grow enough to perform a passage ranging from 2 to 6 weeks. For the evaluation of therapies, i.e. cell viability, we seed 1000 organoids/well in a 96-well cell culture plate, add organoid medium containing the corresponding concentrations of drugs, drug combinations or nanomedicines, and after 72h (37°C, 5%CO2), we measure cell viability using CellTiter Glo 3D following manufacturer’s instructions. | EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC) | Centro de Investigación Príncipe Felipe | 3D organoids model | http://www.VicentResearchLab.com |
| 1.24d_MEDINA | ES | Generation and validation of in-vitro disease model (2/3D cultures and organoids) | Development and validation of classic 2D cell model of adherent tumor cells to the 3D spheroid models better mimicking tumor physiology, enabling to test the effect of extracts/compounds on cells measuring the cellular metabolic activity or analyzing the effect by bioimaging (HCS) , miniaturized and automated assays in 384 format | EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC) | Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía | plate of 3D spheroid model |
More information about individual services, please contact us.